´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14
±³À°ÀÏÀÚ : 2024-04-14
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ¶óº¥´õȦ
±³À°ÁÖÁ¦ : ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÆÄŲ½¼º´¹×ÀÌ»ó¿îµ¿ÁúȯÇÐȸ
´ã´çÀÚ : Ãֹ̼Ò
¿¬¶ôó : 02-6395-2876
À̸ÞÀÏ : movement@kmds.or.kr
±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í »çÀüµî·Ï(Á¤È¸¿ø 50,000¿ø, ÁØȸ¿ø 30,000¿ø, ºñȸ¿ø Àü¹®ÀÇ 100,000¿ø, ºñȸ¿ø Àü°øÀÇ 40,000¿ø) ÇöÀåµî·Ï(Á¤È¸¿ø 60,000¿ø, ÁØȸ¿ø 40,000¿ø, ºñȸ¿ø Àü¹®ÀÇ 120,000¿ø, ºñȸ¿ø Àü°øÀÇ 50,000¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:00~10:40 Session 1. Diagnosis and Management of Miscellaneous Movement Disorders °¼®À±(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:00~09:30 Movement Disorders in In-patient & Emergency Settings ¹Úµ¿±Ô(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:30~10:00 Diagnosis and Management of Tardive Syndromes ¹é°æ¿ø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:00~10:30 Functional Movement Disorders ¹ÚÁ¤ÀÌ(µ¿±¹ÀÇ´ë)
Åä·Ð 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:30~10:40 Q&A °¼®À±(ÇѸ²ÀÇ´ë)
±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:50~12:10 Session 2. Lessons from Historic Clinical Trials ¹ÚÁ¤È£(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:50~11:30 Levodopa and Dopamine Agonists À¯´Þ¶ó(°æÈñÀÇ´ë)
±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 11:30~12:10 MAO-B Inhibitors and COMT Inhibitors Á¤¼®Á¾(¿¬¼¼ÀÇ´ë)
±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 12:10~13:00 Session 3. Case-based Learning - Panels Discussion Á¶¼º¾ç(¿ï»êÀÇ´ë)
Åä·Ð 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 12:10~13:00 How to Optimize the Dopaminergic Treatment of Parkinson¡¯s Disease? °í¼º¹ü/¹ÚÁ¤È£/À¯´Þ¶ó/Á¤¼®Á¾(°í·ÁÀÇ´ë/¼øõÇâÀÇ´ë/°æÈñÀÇ´ë/¿¬¼¼ÀÇ´ë)